Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 17.32B | -2.48%15.08B | 12.23%63.27B | 12.56%15.06B | 11.88%15.46B | 2.85%56.37B | 6.92%15.34B | 4.63%13.84B | 0.26%13.38B | -0.57%13.82B |
| Cost of revenue | 8.16B | -10.56%6.97B | 13.79%31.4B | 13.39%7.57B | 18.16%7.79B | 2.93%27.6B | 3.39%7.48B | 9.27%6.85B | 3.07%6.68B | -3.50%6.59B |
| Gross profit | 9.16B | 5.73%8.11B | 10.75%31.87B | 11.75%7.48B | 6.14%7.67B | 2.77%28.78B | 10.51%7.86B | 0.46%6.99B | -2.39%6.7B | 2.26%7.23B |
| Operating expense | 6.6B | 5.42%6.24B | 8.17%24.74B | 5.35%6.1B | 8.05%5.92B | 5.44%22.87B | -2.02%5.97B | 7.19%5.63B | 7.38%5.79B | 10.67%5.48B |
| Staff costs | ---- | ---- | 8.76%10.15B | ---- | ---- | 6.22%9.33B | ---- | ---- | ---- | ---- |
| Research and development costs | ---- | ---- | 9.22%3.7B | ---- | ---- | 0.09%3.39B | ---- | ---- | ---- | ---- |
| Other operating expenses | ---- | ---- | 7.27%10.9B | ---- | ---- | 6.63%10.16B | ---- | ---- | ---- | ---- |
| Operating profit | 2.57B | 6.78%1.87B | 20.74%7.13B | 52.53%1.39B | 0.17%1.76B | -6.44%5.9B | 86.05%1.88B | -20.28%1.36B | -38.23%908M | -17.36%1.75B |
| Net non-operating interest income (expenses) | 38M | 312.50%33M | -7.69%36M | -7.69%12M | 166.67%8M | 244.44%39M | 350.00%15M | 233.33%8M | 244.44%13M | 150.00%3M |
| Non-operating interest income | --62M | 116.67%52M | 0.00%104M | 3.45%30M | 33.33%24M | 271.43%104M | 230.00%33M | 242.86%24M | 383.33%29M | 260.00%18M |
| Non-operating interest expense | --24M | 18.75%19M | 4.62%68M | 12.50%18M | 6.67%16M | 18.18%65M | 12.50%18M | 23.08%16M | 6.67%16M | 36.36%15M |
| Net investment income | 76M | -239.71%-285M | 425M | 11.56%222M | 358.23%204M | -68.78%64M | -43.47%199M | -135.43%-79M | ||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 59M | 462.78%809M | -252.63%-87M | 100.00%30M | -957.69%-223M | 209.62%57M | 75.32%-19M | 400.00%35M | 15M | 44.44%26M |
| Income from associates and other participating interests | 6M | 150.00%1M | -92.11%3M | -130.77%-4M | -111.76%-2M | -41.54%38M | 0 | -55.56%8M | -31.58%13M | 6.25%17M |
| Special income (charges) | 2M | -200.00%-1M | -99.12%3M | -900.00%-10M | -87.50%1M | 199.13%342M | 101.02%4M | 33,000.00%331M | -107.14%-1M | -76.47%8M |
| Less:Other special charges | ---2M | 200.00%1M | 76.92%-3M | 900.00%10M | 87.50%-1M | 75.47%-13M | 0.00%-4M | -100.00%-2M | 107.14%1M | 76.47%-8M |
| Less:Write off | ---- | ---- | --0 | ---- | ---- | -182.66%-329M | --0 | ---- | ---- | ---- |
| Other non-operating income (expenses) | 12M | -46.67%8M | -60.09%87M | -25.93%20M | -50.00%15M | 190.67%218M | 600.00%112M | 276.92%49M | 50.00%27M | 7.14%30M |
| Income before tax | 2.76B | 38.74%2.44B | 15.04%7.59B | 40.58%1.66B | 0.11%1.76B | 0.32%6.6B | 445.18%1.81B | -4.68%1.85B | -36.84%1.18B | -27.89%1.76B |
| Income tax | 699M | 44.42%660M | -4.58%1.89B | 13.87%427M | -20.24%457M | 9.01%1.99B | 500.00%600M | -19.37%437M | -23.31%375M | -16.96%573M |
| Net income | 2.06B | 36.74%1.78B | 23.51%5.69B | 53.12%1.23B | 9.97%1.3B | -3.01%4.61B | 421.12%1.21B | 1.14%1.42B | -41.76%802M | -32.17%1.18B |
| Net income continuous operations | --2.06B | 36.74%1.78B | 23.49%5.69B | 53.05%1.23B | 9.97%1.3B | -3.01%4.61B | 421.55%1.21B | 1.00%1.42B | -41.64%803M | -32.21%1.18B |
| Noncontrolling interests | 1M | 1M | 300.00%4M | 0 | 0 | 1M | 1M | 0 | 0 | 0 |
| Net income attributable to the company | 2.06B | 36.66%1.78B | 23.46%5.69B | 52.80%1.23B | 10.07%1.3B | -3.03%4.61B | 420.69%1.21B | 1.07%1.42B | -41.68%803M | -32.19%1.18B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 2.06B | 36.66%1.78B | 23.46%5.69B | 52.80%1.23B | 10.07%1.3B | -3.03%4.61B | 420.69%1.21B | 1.07%1.42B | -41.68%803M | -32.19%1.18B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 57.83 | 36.21%49.92 | 23.23%159.86 | 52.50%34.45 | 10.09%36.65 | -3.03%129.73 | 420.67%34 | 1.12%39.85 | -41.75%22.59 | -32.16%33.29 |
| Diluted earnings per share | 57.35 | 36.41%49.57 | 23.31%158.68 | 52.79%34.21 | 9.95%36.34 | -3.15%128.68 | 422.48%33.7 | 1.07%39.54 | -41.86%22.39 | -32.25%33.05 |
| Dividend per share | 0 | 0 | 0.00%40 | 0.00%20 | 0 | 11.11%40 | 11.11%20 | 0 | 11.11%20 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |